Lymphoma & Plasma Cell Disorders
News
Extended virus shedding after COVID-19 in some patients with cancer
Some patients, including stem cell transplant and CAR T recipients, may require extended periods of isolation.
Conference Coverage
Durable responses with anti-BCMA CAR T-cell for multiple myeloma
Seventy-two percent of patients with relapsed/refractory multiple myeloma had ongoing responses at the time of data cutoff in the CARTITUDE-1...
Conference Coverage
Allogeneic transplant leads to durable remissions in T-cell lymphomas
Retrospective study demonstrates overall survival over 50% at 5 years, though transplant-related mortality and graft-versus-host disease need to...
Conference Coverage
ZUMA-5: Axi-cel yields high response rate in indolent NHL
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...
Conference Coverage
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
Cancer patients treated with immune checkpoint inhibitors are not significantly more likely to develop or die from COVID-19, two studies suggest...
News
Circulating miRNA could be a potential biomarker for early diagnosis of MM
A meta-analysis found that using circulating microRNAs had high sensitivity and specificity in the early diagnosis of multiple myeloma.
News
Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia
The presence of “many or very many nevi [moles]” was particularly associated with the risk of CLL.
Article
Using telehealth to deliver palliative care to cancer patients
Dr. Alan Lyss discusses the use of telehealth for palliative cancer care, including results from the REACH PC trial.
Conference Coverage
Home care for bortezomib safe and reduces hospital visits in myeloma patients
Conference Coverage
Lower BP and better tumor control with drug combo?
